All In Biotech

Drug Trial Radar · NCT07019779

Study of CM518D1 in Patients With Advanced Solid Tumors

A Multicenter, Open-Label, Phase I/II Clinical Study to Evaluate CM518D1 in the Treatment of Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 434 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

434

Planned (sponsor's estimate)

Start

Jun 27, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Jun 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an interventional study to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of CM518D1 in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • CM518D1Biological

    CM518D1 will be administered intravenously once every 3 weeks (Q3W) in 6 predetermined dose levels.

  • CM518D1Biological

    CM518D1 will be administered intravenously once every 3 weeks (Q3W) in one or more potential recommended phase 2 dose(RP2D).

  • CM518D1Biological

    CM518D1 will be administered intravenously once every 3 weeks (Q3W) in different types of solid tumor cohorts.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT)-Phase I dose escalationTime frame: First cycle (21 days)
  2. Incidence of adverse events (AEs), serious adverse events (SAEs), and specific laboratory abnormalities-Phase I dose escalationTime frame: Through study completion, an average of 2 years.
  3. Incidence of adverse events (AEs), serious adverse events (SAEs), and specific laboratory abnormalities-Phase I dose expansionTime frame: Through study completion, an average of 2 years.]
  4. Preliminary efficacy-Phase I dose expansionTime frame: Through study completion, an average of 2 years.]
  5. Objective response rate (ORR)-Phase IITime frame: Through study completion, an average of 2 years.]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center (SYSUCC)

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.